Gedeon Richter Plc. announces that the European Commission has granted marketing authorization to Reagila® (cariprazine) a novel antipsychotic for the treatment of schizophrenia in adult patients.
Gedeon Richter Plc. announces that the European Commission has granted marketing authorization to Reagila® (cariprazine) a novel antipsychotic for the treatment of schizophrenia in adult patients.